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Abstract:  Background:  To  evaluate  agreement  between  cardiovascular  risk  in  sedentary 
patients as estimated by the new Framingham-D’Agostino scale and by the SCORE chart, 
and to describe the patient characteristics associated with the observed disagreement between 
the scales. Design: A cross-sectional study was undertaken involving a systematic sample of 
2,295 sedentary individuals between 40–65 years of age seen for any reason in 56 primary 
care  offices.  An  estimation  was  made  of  the  Pearson  correlation  coefficient  and  kappa 
statistic  for  the  classification  of  high  risk  subjects  (≥20%  according  to  the  Framingham-
D’Agostino scale, and ≥5% according to SCORE). Polytomous logistic regression models 
were fitted to identify the variables associated with the discordance between the two scales. 
Results:  The  mean  risk  in  males  (35%)  was  19.5%  ±  13%  with  D’Agostino  scale,  and  
3.2% ±  3.3% with SCORE. Among females, they were 8.1% ±  6.8% and 1.2% ±  2.2%, 
respectively.  The  correlation  between  the  two  scales  was  0.874  in  males  (95%  CI:  
0.857–0.889) and 0.818 in females (95% CI: 0.800–0.834), while the kappa index was 0.50 
in males (95% CI: 0.44%–0.56%) and 0.61 in females (95% CI: 0.52%–0.71%). The most 
frequent  disagreement,  characterized  by  high  risk  according  to  D’Agostino  scale  but not 
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according to SCORE, was much more prevalent among males and proved more probable 
with increasing age and increased LDL-cholesterol, triglyceride and systolic blood pressure 
values, as well as among those who used antihypertensive drugs and smokers. Conclusions: 
The quantitative correlation between the two scales is very high. Patient categorization as 
corresponding to high risk generates disagreements, mainly among males, where agreement 
between the two classifications is only moderate. 
Keywords: cardiovascular diseases; risk assessment; risk factors; sedentary 
 
1. Introduction 
 
The stratification of cardiovascular risk (CVR) is the most cost-effective way to define the priorities 
of  cardiovascular  prevention  in  asymptomatic  patients,  and  is  currently  the  best  available  tool  for 
making treatment decisions in clinical practice [1-3].  
The equations designed to estimate CVR are based on follow-up of population cohorts sufficiently 
large  to  secure  the  required  precision.  In  Europe,  use  of  the  SCORE  (Systematic  Coronary  Risk 
Evaluation)  chart  is  recommended,  based  on  cohorts  from  12  European  countries;  this  instrument 
estimates mortality risk due to cardiovascular diseases [4]. Different countries, including Spain [5-8], 
have carried out specific adaptations of the original charts, since they generally overestimate the true 
cardiovascular  risk.  However,  it  has  been  seen  that  the  Spanish  adaptation  underestimates 
cardiovascular mortality [5]. Recently, a new scale (D’Agostino) based on the Framingham Heart Study 
has been developed to estimate the risk of new vascular events—both coronary and cerebrovascular [9]. 
A review of the multiple studies published in recent years reveals that there is no ideal scale for 
assessing CVR in Mediterranean populations. The original Framingham function [10,11], in its different 
versions, identifies more high CVR patients than the SCORE chart [12,13]. However, its calibration for 
the  Spanish  population  (REGICOR)  [14,15]  identifies  fewer  high  CVR  patients  than  the  original  
scale [16,17], and agreement in identification of patients with high CVR [18-21] is low. It should be 
kept in mind that the scales derived from the Framingham function estimate the incidence of coronary 
disease, with the exception of the D’Agostino scale, which estimates global cardiovascular morbidity 
and  mortality,  whereas  the  SCORE  estimates  cardiovascular  mortality.  The  Framingham  scales  are 
commonly used as a standard for evaluating other methods, such as the presence of calcium in the 
coronary artery [22], and also for assessing the effectiveness of certain interventions [23]. Agreement or 
concordance  between  the  SCORE  and  D’Agostino  scales  has  been  analyzed  in  hypertensive  
patients [24], but not in the general population, or specifically in sedentary subjects. 
Thus, the aims of this study were to assess the agreement between these scales in sedentary patients 
aged 40–65 years, and to describe the patient characteristics associated to disagreement between the 
scales in identifying patients with high CVR. The objective is to evaluate the convergent validity of the 
new scale, accrediting its use in clinical practice for the detection of patients with a high risk of suffering 
cardiovascular disease. Int. J. Environ. Res. Public Health 2009, 6                 
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2. Methods 
 
2.1. Study Design and Patients 
 
A cross-sectional analysis was made of the participants in a randomized, multicenter clinical trial 
carried  out  in  Spain  to  assess  a  physical  activity  promoting  program  in  primary  care  [25,26].  The 
participants were recruited from 11 primary care centers in eight Spanish Autonomous Communities 
collaborating with the Research Network in Preventive and Health Promoting Activities (redIAPP). All 
sedentary  individuals  between  20–80  years  of  age  seen  for  any  reason  in  56  primary  care  offices 
between October 2003 and May 2004 were considered eligible for participation in the clinical trial. On 
one or two days of the week, the primary care physicians recruited those subjects failing to meet the 
minimum physical activity recommendations [27], in a systematic patient sample previously selected by 
the nursing personnel dedicated to the research project from among all the individuals seen in daily 
practice.  The  participants  received  an  information  sheet  and  signed  a  consent  form  before  the 
measurements were made. The patients included in the analysis were between 40–65 years of age, with 
no history of established cardiovascular disease. A detailed description of the recruitment process and 
the characteristics of the patients included in the clinical trial has been published elsewhere [25,26]. 
 
2.2. Measurements 
 
The measurements of body mass index (BMI) and blood pressure using OMROM M7® pressure 
recorders were made by trained nursing personnel, following the recommendations of the European 
Society of Hypertension [28]. The variables needed for calculating risk with both scales were obtained 
from the patient case histories. Morbidity-mortality risk calculated with the D’Agostino scale [9]: age, 
sex, total cholesterol, high-density lipoprotein cholesterol (HDL-C), systolic blood pressure (SBP, drug 
treatment for arterial hypertension (AHT), smoking, and history of diabetes mellitus. Cardiovascular 
mortality risk calculated with the SCORE [4] for low risk countries: age, sex, total cholesterol, SBP, 
and  smoking.  This  instrument  does not include diabetes as risk factor, but the authors recommend 
multiplication by four in females and by two in males in the presence of diabetes. This recommendation 
was followed in our study. Blood glucose and full lipid profile were also recorded. Blood lipid and 
glucose levels were measured on a blind basis by the laboratories associated to the participating primary 
care centers, after patient fasting for at least eight hours. Smoking was self-reported.  
 
2.3. Patient Classification According to Risk 
 
Patients at high CVR were taken to be those with a ≥20% cardiovascular morbidity-mortality risk 
according to the Framingham-D’Agostino scale [9], and with a risk of cardiovascular death of ≥5% 
according to the SCORE charts [4].  
 
 Int. J. Environ. Res. Public Health 2009, 6                 
 
 
2803 
2.4. Statistical Analysis 
 
Agreement between the two scales was quantified by the Pearson correlation coefficient, and was 
qualitatively assessed by the kappa statistic for high risk categorization—― excellent‖ agreement being 
considered  for  values  of  0.81–1,  ― good‖  agreement  for  0.61–0.80,  ― moderate‖  agreement  for  
0.41–0.60, ― slight‖ agreement for 0.21–0.40, and ― poor‖ agreement for 0–0.20 [29]. 
To evaluate the association between patient characteristics and disagreement in risk categorization or 
classification  between  the  two  scales,  a  polytomous  logistic  regression  model  was  fitted  in  which 
analysis  was  made  of  the  probability of agreement on both scales versus disagreement with a high 
D’Agostino score and a non-high SCORE, and versus disagreement with a high SCORE and a non-high 
D’Agostino score. As independent variables, we included patient age, sex, BMI, smoking, the presence 
or absence of diabetes mellitus, total cholesterol, HDL-cholesterol, low-density lipoprotein cholesterol 
(LDL-C),  systolic  blood  pressure  (SBP),  diastolic  blood  pressure  (DBP),  and  the  use  of 
antihypertensive  medication.  Modification  of  these  effects  by  gender  was  moreover  admitted.  All 
calculations  were  made  using  the  Statistical  Analysis  System  (SAS)  version  9.2  software  package  
(SAS Institute Inc., Cary, NC, USA; 2008). 
 
3. Results 
 
Of the sample of 4,927 subjects between 20–80 years of age selected for the original study, 2,295 
(46.5%) were within the age range recommended for use of the two scales (45–65 years), with no 
history of cardiovascular disease, and presenting the data needed for risk calculation. Males (35% of the 
total) had a higher percentage of diabetics, smokers and hypertension, a poorer lipid profile, and higher 
systolic  and  diastolic  blood  pressure  values.  The  mean  risk  among  males  as  determined  by  the 
D’Agostino  score,  which  is  used  with  a  threshold  of  20%  for  high  risk,  was  19.5%  ±  13%,  versus  
3.2% ±  3.3% according to the SCORE, with a threshold of 5% for high risk. The corresponding female 
values were 8.1% ±  6.8% and 1.2% ±  2.2%, respectively, with a threshold for high risk same than men 
(Table 1). 
 
Table 1. Characteristics of study patients, overall and by sex. 
  All (n = 2295 )  Men (n = 805)  Women (n = 1490)  p* 
SCORE risk  1.91 ±  2.78  3.18 ±  3.30  1.23 ±  2.16  <0.0001 
D’Agostino risk  12.09 ±  10.89   19.50 ±  12.92  8.08 ±  6.83  <0.0001 
SCORE risk > 5%  212 (9.24%)  151 (18.76%)  61 (4.09%)  <0.0001 
D’Agostino risk > 20%  396 (17.25%)  308 (38.26%)  88 (5.91%)  <0.0001 
Age (years)  52.93 ±  7.32  53.15 ±  7.24  52.81 ±  7.35  0.2989 
Overweight (BMI> 30)  649 (28.30%)  215 (26.77%)  434 (29.13%)  0.2328 
Smoking   586 (25.53%)  273 (33.91%)  313 (21.01%)  <0.0001 
Diabetes  225 (9.80%)  114 (14.16%)  111 (7.45%)  <0.0001 
High Cholesterol (Cholesterol >250 mg/dL)  424 (18.47%)  151 (18.76%)  273 (18.32%)  0.7975 
Hypertensive  703 (30.63%)  296 (36.77%)  407 (27.32%)  <0.0001 
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Table 1. Cont. 
BMI  27.97 ±  4.60  28.12 ±  3.72  27.89 ±  5.01  0.2038 
Glycaemia (mg/dL)  99.60 ±  24.24  105.48 ±  28.29  96.40 ±  21.06  <0.0001 
Ratio Cholesterol total / cHDL  3.96 ±  1.17  4.41 ±  1.22  3.72 ±  1.06  <0.0001 
Ratio log(Triglycerides) / HDL  0.09 ±  0.03  0.10 ±  0.03   0.08 ±  0.03  <0.0001 
Cholesterol total (mg/dL)  218.11 ±  24.24  217.34 ±  37.20  218.53 ±  36.37  0.4594 
cHDL (mg/dL)  58.81 ±  17.29  52.01 ±  14.02  62.48 ±  17.78  <0.0001 
cLDL (mg/dL)  136.25 ±  33.92  138.28 ±  34.93  135.15 ±  33.32  0.0369 
Triglycerides (mg/dL)  120.12 ±  71.79  146.32 ±  86.51  105.947 ±  57.65  <0.0001 
Systolic blood pressure (mmHg)  130.98 ±  18.21  135.85 ±  16.88  128.34 ±  18.37  <0.0001 
Diastolic blood pressure (mmHg)  79.65 ±  10.52  81.83 ±  10.51  78.47 ±  10.33  <0.0001 
Antihypertensive drugs  559 (24.79%)  246 (30.56%)  323 (21.68%)  <0.0001 
(mean ±  standard deviation or number and percent). 
BMI: Body mass index; HDL: high density lipoprotein; cHDL: Cholesterol high density lipoprotein; cLDL: low density 
lipoprotein. 
 *Difference between men and women. t student or ANOVA by quantitative variables and chi-square by qualitative. 
 
The correlation between the two scales was 0.859 (95%CI: 0.848–0.870) considered globally, 0.874 
(95%CI: 0.857–0.889) in males, and 0.818 (95%CI 0.800–0.834) in females. With regards to the risk 
category, the percentage of patients at high risk according to the SCORE was 18.8% in males and 4.1% 
in females, while the D’Agostino scale identified high risk for 38.3% of the males and 5.9% of the 
females. Table 2 shows the agreement between the two scales, with a kappa index of 0.50 in males 
(95%CI: 0.44%–0.56%) and 0.61 in females (95% CI: 0.52%–0.71%). The greatest disagreement was 
found among the high risk males as established by the D’Agostino scale; of these subjects, 20.4% did 
not show high risk according to the SCORE. Using the D’Agostino vs. SCORE methods will give the 
same classification for 80% of men and 96% of women (Table 2). 
 
Table  2.  Classification  of  cardiovascular  risk  in  the  high  and  non  high  categories. 
Agreement in the high and low risk categories.  
  
 Assessment by SCORE 
Assessment by D’Agostino    
Overall 
  Non-high CVR  High CVR 
Men n=805       
Non-high CVR  490 (60.87%)  164 (20.37%)  654 
High CVR  7 (0.87%)  144(17.89%)  151 
Overall  497  308  805 
Kappa index: 0.50 (0.44–0.56)       
Women n = 1,490       
Non-high CVR  1388 (93.15%)  41 (2.75%)  1429 
High CVR  14 (0.94%)  47 (3.15%)  61 
Overall  1,402  88  1,490 
Kappa index: 0.61 (0.52–0.71)        
CVR: Cardiovascular risk. The table shows n (%) by sex from overall people. Int. J. Environ. Res. Public Health 2009, 6                 
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Table 3 shows the variables of the final polytomous logistic regression model seen to be associated 
with  disagreement  between  the  two  scales.  After  simultaneously  fitting  for  the  rest  of  covariables 
included in the model, the most frequent disagreement, characterized by high risk according to the 
D’Agostino scale but not according to the SCORE, was much more prevalent among males and proved 
more  probable  with  increasing  age  and  increased  LDL-cholesterol,  triglyceride  and  systolic  blood 
pressure values, as well as among those who used antihypertensive drugs and smokers. While positive, 
the  magnitude  of  the  association  between  these  variables  and  the  mentioned  disagreement  was 
significantly  smaller  among  females  (p  <  0.03).  The  presence  of  diabetes  mellitus  and  higher  
HDL-cholesterol levels make such disagreement less probable in both males and females (Table 3). 
 
Table  3.  Variables  associated  to  discrepancies  in  classification  as  high  CVR  between 
SCORE and D’Agostino scales.  
 
D’Agostino high and SCORE Non 
high * 
D’Agostino Non high and SCORE 
high** 
Odds Ratio (IC 95%)  Odds Ratio (IC 95%) 
Age (1 year)     
 Men  1.32 (1.18–1.47)  13.11 (1.85–92.75) 
 Women  1.14 (1.09–1.18)  7.12 (1.33–38.12) 
Age*sex   0.99 (0.98–0.99)  0.88 (0.79–0.98) 
Sex (Men)***  10.65 (3.26–34.71)   
BMI ( kg/m
2)    11.13 (9.22–13.44) 
Diabetes   0.36 (0.20–0.65)  103.09 (21.77–488.17) 
Cholesterol HDL (mg/dl)  0.49 (0.40–0.61)  1.56 (1.23–1.98) 
Cholesterol LDL (mg/dl)  1.18 (1.12–1.25)   
Triglycerides (mg/dl)    0.92 (0.86–0.99) 
 Men  1.09 (1.03–1.15)   
 Women  1 (0.98–1.03)   
Systolic blood pressure (mmHg)     
 Men  2.11 (1.66–2.68)  0.70 (0.48–1.02) 
 Women  1.09 (0.95–1.24)  2.74 (1.21–6.21) 
Antihypertensive drugs    0.14 (0.04–0.57) 
 Men  22.33 (5.97–83.52)   
 Women  4.85 (3.08–7.63)   
Smoker      
 Men  13.59 (4.82–38.35)   
 Women  2.43 (1.56–3.80)   
*  Interaction  between  sex  and  aged,  smokers,  Triglycerides,  systolic  blood  pressure  and 
antihypertensive drugs; p < 0.03.  
** Interaction between sex, aged and systolic blood pressure; p < 0.05.  
*** Effect to be man when aged, triglycerides and systolic blood pressure take mean value and not on 
antihypertensive treatment and not smokers. Int. J. Environ. Res. Public Health 2009, 6                 
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The probability of observing disagreements due to a high SCORE and non-high D’Agostino score 
was not correlated to patient sex at the mean levels of the rest of the covariables. The characteristics 
associated with increased probability in disagreements were older age, greater BMI, the presence of 
diabetes  mellitus,  HDL-cholesterol  levels  and  systolic  blood  pressure  (the  latter  parameter  only  in 
females). Systolic blood pressure reduced the probability of disagreement of this kind in males, while 
triglyceride  levels  and  the  use  of  antihypertensive  medication  reduced the probability in both  sexes 
(Table 3). 
 
4. Discussion 
 
Our  results  indicate  a  strong  correlation  between  cardiovascular  mortality  as  estimated  by  the 
SCORE [4] and the risk of developing cardiovascular disease as estimated by the D’Agostino scale [9]. 
The problem arises when as happens in deciding treatment in clinical practice, high risk is or is not 
assumed for patients that exceed the 5% mortality threshold estimated by the SCORE, or the 20% risk 
threshold estimated by the D’Agostino scale. The agreement between the two instruments in relation to 
this classification of high risk patients is good in the case of females, but only moderate in the case of 
males. The most frequent disagreement is found among males classified as being at high risk according 
to the D’Agostino equation. In addition to male status, a considerable number of characteristics such as 
older age, smoking, increased systolic blood pressure, a poorer lipid profile and antihypertensive drug 
therapy define a group of patients in which the risk of cardiovascular disease could be underestimated or 
overestimated if only the SCORE or the D’Agostino scale were used, respectively. 
The percentage of patients classified in this study as having a high CVR using the SCORE equation 
is  similar  to  that  reported  by  other  studies  in  the  primary  care  setting  [19],  in  the  general  
population  [21], or in hypertensive individuals [30]. The D’Agostino scale classifies twice as many 
patients  as  being  at  high  risk  compared  with  the  SCORE,  and  both  scales  classify  a  much  larger 
proportion of males as presenting high risk. In this sense, for each female classified as being at high risk, 
the SCORE classifies 4.5 males and the D’Agostino scale classifies 6 males as presenting high risk.  
These data indicate that the scale derived from the D’Agostino equation identify more high risk CVR 
subject  than  SCORE—despite  the  fact  that  it  calculates  CVR,  not  only  coronary  risk  as  before. 
Calibration of this scale in our population would therefore be necessary. 
No comparison has been made in our setting between the SCORE and the D’Agostino scale at the 
20%  high  risk  cutoff  point  in  a  sample  of  sedentary  patients  between  40–65 years of age without 
cardiovascular  antecedents—though  many  studies  have  compared  different  Framingham  
versions  [10,11]  with  the  SCORE.  In  studies  involving  subjects  seen  in  primary  care  centers,  the 
SCORE and Framingham estimate higher risk—thus indicating lipid-lowering drug treatment in a larger 
number  of  patients  than  the  REGICOR  [16,21].  The  scales  compared  in  this study measure CVR, 
mortality risk and morbidity-mortality risk. This is probably why agreement between the two scales 
shows  a  kappa  index  of  0.58,  which  is  better  than  that  published  by  other  authors  comparing  the 
Framingham-REGICOR  and  SCORE  [19,21,30],  or  the  Framingham and SCORE [12,13,30], since 
these  are  equations  that  predict  different  cardiovascular  events  (coronary  morbidity-mortality  and 
cardiovascular mortality).  Int. J. Environ. Res. Public Health 2009, 6                 
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The percentage of patients showing disagreement between the two instruments on being classified as 
high risk subjects was 54.2%. Of every 100 males with disagreement, 97 showed high risk according to 
the D’Agostino scale and non-high risk according to the SCORE, while only three showed non-high 
risk according to the D’Agostino scale and high risk as determined by the SCORE. However, of every 
100 females with disagreement, approximately 53 showed high risk according to the D’Agostino scale 
and  non-high  risk  according  to  the  SCORE,  while  47  showed  non-high  risk  according  to  the 
D’Agostino scale and high risk as determined by the SCORE. These figures, while substantial, are lower 
than the disagreements reported in other studies [13,19,21]. 
The males with high risk according to the D’Agostino scale and non-high risk as determined by the 
SCORE (i.e., the most frequent profile) were smokers, had higher blood pressure or were hypertensive, 
and  presented  higher  total  cholesterol,  LDL-cholesterol  and  triglyceride  levels,  and  lower  
HDL-cholesterol concentrations. Specifically, the subgroup of older males who smoke and with high 
systolic blood pressure, a poor lipid profile and antihypertensive drug therapy is clinically problematical, 
because it is the most likely to present a classification disagreement as a high risk profile. This profile 
has already been reported in the study published by Gil et al. [16].  
In such subjects it would be accepted that the actual risk could be higher than the risk as calculated 
with the SCORE. These patients would have to be regarded as presenting an increased risk, and would 
have to be managed on an individualized basis. 
A main limitation of this study is that the sample only represents the sedentary population between 
40–65 years of age seen in the primary care setting—excluding patients that do not seek medical care, 
and active individuals.  
Other limitations that must be taken into account when interpreting the results are those inherent to 
the actual scales in determining CVR. The SCORE only estimates cardiovascular mortality  and the 
population in the 40-65 years age range, while the Framingham instrument comprises a population with 
far higher CVR than the Spanish population.  
Nevertheless, the design is valid for assessing agreement by sexes between the two scales, without 
interfering with comparison of the two equations—though the selection of patients limits the external 
validity of the study when extrapolating the results to the general population. 
We  conclude  that  although  a  strong  correlation  is  observed  between  the  two  scales,  there  is 
disagreement in the identification of high risk patients between the SCORE for countries with a low 
cardiovascular risk and the D’Agostino scale—fundamentally among males. This may justify revision of 
the  cutoff  values  beyond which patients are classified as being at high risk. The description of the 
characteristics of those males presenting disagreement could allow improved clinical evaluation of CVR 
and help identify those subjects who despite a non-high risk as determined by the SCORE, may actually 
have a higher cardiovascular risk than estimated by the latter scale.  
These findings must be confirmed by prospective studies, though their importance is explained by the 
fact that they underscore the need for improved validity of the scales—particularly among males—in 
order to optimize their usefulness in clinical practice. Cardiovascular disease incidence and mortality 
studies are needed to develop risk scales based on the populations in which they are going to be used. 
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Carmen  Garcıa,  Marıa  Angeles  Gabriel,  Marıa  Luscinda  Velazquez,  Natividad  Ortega,  Marıa  josé 
Segura,  Rodrigo Cerrillo, and Patricia Lopez).  Castilla y Leon Health Service: Casa Barco Health 
Center–  Valladolid  (Carmen  Fernandez,  Amparo  Gomez,  Miguel  Angel  Dıez,  Ruperto  Sanz,  Luis 
Miguel Quintero, and Jose Ignacio Recio), La Alamedilla Health Center–Salamanca (Luis Garcıa, Jose 
Antonio Iglesias, Manuel Gomez, Emilio Ramos, Pilar Moreno, Yolanda Castano, and Nadia Carrillo). 
Galicia  Health  Service:  Sardoma  Health  Center–  Vigo  (Pilar  Gayoso,  Luciano  Casariego,  Manuel 
Domınguez, Jose Ramon Moliner, Fernando Lago, Marıa Concepcion Cruces, and Marisa Enrıquez). 
Madrid Health Service: Guayaba Health Center–Madrid (Tomas Gomez Gascon, Javier Martınez, Jose 
Antonio Granados, Marıa Angeles Fernandez, Marıa Isabel Gutierrez, Carlos San Andrés, Concepcion 
Vargas-Machuca, and Cristina Dıaz). 
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